ACR Appropriateness Criteria® on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II
Author Department
Medicine
Document Type
Article, Peer-reviewed
Publication Date
5-1-2011
Abstract
Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists. Copyright © 2011 American College of Radiology. Published by Elsevier Inc. All rights reserved.
Publication ISSN
0884-8734
Recommended Citation
Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria® on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II J Am Coll Radiol 2011 May;8(5):302-8.